 |
|
Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis
Tae Hyung Kim, Young Kul Jung, Hyung Joon Yim, Joo Won Baik, Sun Young Yim, Young-Sun Lee, Yeon Seok Seo, Ji Hoon Kim, Jong Eun Yeon, Kwan Soo Byun
Clin Mol Hepatol. 2022;28(4):876-889. Published online 2022 Sep 19 DOI: https://doi.org/10.3350/cmh.2022.0231
|
|
Citations to this article as recorded by
 Correspondence on Letter regarding “Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis”
Tae Hyung Kim, Young Kul Jung, Hyung Joon Yim
Clinical and Molecular Hepatology.2023; 29(1): 173. CrossRef Letter regarding “Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis”
Do Seon Song, U Im Chang, Jin Mo Yang
Clinical and Molecular Hepatology.2023; 29(1): 165. CrossRef Interaction between sarcopenia and nonalcoholic fatty liver disease
Sae Kyung Joo, Won Kim
Clinical and Molecular Hepatology.2023; 29(Suppl): S68. CrossRef MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study
Eugene Han, Ho Soo Chun, Yong‐ho Lee, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Byung‐Wan Lee, Eun Seok Kang, Bong‐Soo Cha, Sang Hoon Ahn, Seung Up Kim
Journal of Gastroenterology and Hepatology.2023;[Epub] CrossRef Sarcopenia in cirrhosis: Prospects for therapy targeted to gut microbiota
Roman Maslennikov, Aliya Alieva, Elena Poluektova, Yury Zharikov, Andrey Suslov, Yana Letyagina, Ekaterina Vasileva, Anna Levshina, Evgenii Kozlov, Vladimir Ivashkin
World Journal of Gastroenterology.2023; 29(27): 4236. CrossRef
|